Home Gilead TrialWatch: Gilead HIV Drug Descovy Meets Endpoint

TrialWatch: Gilead HIV Drug Descovy Meets Endpoint

279
0

Gilead reports that the next generation HIV medication, Descovy, has provided non-inferior to one of its mainstay therapies, Tuvada, in a late-stage trial that the big biotech says is the largest HIV prevention study conducted to date. The two year DISCOVER trial enrolled nearly 5,400 participants at risk for sexually acquired HIV infection. They received once-daily regimens of either Truvada or Descovy for HIV pre-exposure prophylaxis (PrEP). The results reveal that Descovy met the study’s primary endpoint. The sponsor reports that the investigational drug outperformed Truvada on secondary endpoints of bone and renal safety.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.